0001713695-18-000004.txt : 20180425 0001713695-18-000004.hdr.sgml : 20180425 20180425161950 ACCESSION NUMBER: 0001713695-18-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180425 DATE AS OF CHANGE: 20180425 EFFECTIVENESS DATE: 20180425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MATEON THERAPEUTICS INC CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-310989 FILM NUMBER: 18774590 BUSINESS ADDRESS: STREET 1: 701 GATEWAY BLVD. STREET 2: SUITE 210 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 701 GATEWAY BLVD. STREET 2: SUITE 210 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: OXIGENE INC DATE OF NAME CHANGE: 19930628 D 1 primary_doc.xml X0708 D LIVE 0000908259 MATEON THERAPEUTICS INC 701 GATEWAY BLVD. SUITE 210 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 650-635-7000 DELAWARE OXIGENE INC Corporation true William D. Schwieterman 701 Gateway Blvd., Suite 210 South San Francisco CA CALIFORNIA 94080 Executive Officer Director David J. Chaplin 701 Gateway Blvd., Suite 210 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Simon C. Pedder 701 Gateway Blvd., Suite 210 South San Francisco CA CALIFORNIA 94080 Director Donald R. Reynolds 701 Gateway Blvd., Suite 210 South San Francisco CA CALIFORNIA 94080 Director Bobby W. Sandage, Jr. 701 Gateway Blvd., Suite 210 South San Francisco CA CALIFORNIA 94080 Director Matthew M. Loar 701 Gateway Blvd., Suite 210 South San Francisco CA CALIFORNIA 94080 Executive Officer Biotechnology No Revenues 06b false 2018-04-12 false true true false 25000 Divine Capital Markets LLC 118212 None None 39 Broadway, 36th Floor New York NY NEW YORK 10006 All States false 12000000 2925000 9075000 Total Offering amount includes approximately $6,000,000 in proceeds receivable assuming full exercise of Warrants offered. false 38 400000 true 0 Divine as placement agent is eligible to receive an amount equal to 10% of the gross proceeds raised upon the sale of shares, and a Warrant to purchase that number of shares of common stock equal to 10% of the aggregate number of shares sold. 0 false MATEON THERAPEUTICS INC /s/ Matthew M. Loar Matthew M. Loar Chief Financial Officer 2018-04-25